JP2024528036A - Sarm1阻害剤としての置換ピリジン誘導体 - Google Patents

Sarm1阻害剤としての置換ピリジン誘導体 Download PDF

Info

Publication number
JP2024528036A
JP2024528036A JP2024505223A JP2024505223A JP2024528036A JP 2024528036 A JP2024528036 A JP 2024528036A JP 2024505223 A JP2024505223 A JP 2024505223A JP 2024505223 A JP2024505223 A JP 2024505223A JP 2024528036 A JP2024528036 A JP 2024528036A
Authority
JP
Japan
Prior art keywords
imidazol
methyl
pyridin
pharma
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528036A5 (enExample
Inventor
コルリ,ラオ
マイケル テグリー,クリストファー
ヂゥー,リウシェン
ポメロイ ブラウン,ショーン
スチュワート タスカー,アンドリュー
エー. グライス,シェリル
ハワード レイノルズ,チャールズ
Original Assignee
ヌラ バイオ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌラ バイオ,インク. filed Critical ヌラ バイオ,インク.
Publication of JP2024528036A publication Critical patent/JP2024528036A/ja
Publication of JP2024528036A5 publication Critical patent/JP2024528036A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2024505223A 2021-07-28 2022-07-27 Sarm1阻害剤としての置換ピリジン誘導体 Pending JP2024528036A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163226557P 2021-07-28 2021-07-28
US63/226,557 2021-07-28
US202263305103P 2022-01-31 2022-01-31
US63/305,103 2022-01-31
US202263368034P 2022-07-08 2022-07-08
US63/368,034 2022-07-08
PCT/US2022/038577 WO2023009663A1 (en) 2021-07-28 2022-07-27 Substituted pyridine derivatives as sarm1 inhibitors

Publications (2)

Publication Number Publication Date
JP2024528036A true JP2024528036A (ja) 2024-07-26
JP2024528036A5 JP2024528036A5 (enExample) 2025-07-14

Family

ID=85087993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505223A Pending JP2024528036A (ja) 2021-07-28 2022-07-27 Sarm1阻害剤としての置換ピリジン誘導体

Country Status (12)

Country Link
US (2) US11629136B1 (enExample)
EP (1) EP4376840A4 (enExample)
JP (1) JP2024528036A (enExample)
KR (1) KR20240041987A (enExample)
AU (1) AU2022320699A1 (enExample)
CA (1) CA3226869A1 (enExample)
CL (1) CL2024000239A1 (enExample)
CO (1) CO2024001716A2 (enExample)
IL (1) IL310403A (enExample)
MX (1) MX2024001322A (enExample)
TW (1) TW202313009A (enExample)
WO (1) WO2023009663A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
EP4304586A4 (en) 2021-03-10 2025-04-02 Jnana Therapeutics Inc. SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION
EP4376840A4 (en) * 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
CN113655155A (zh) * 2021-07-28 2021-11-16 任贤金 一种测定sph3127有关物质的方法
EP4562001A1 (en) * 2022-07-27 2025-06-04 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN120424050A (zh) * 2024-02-05 2025-08-05 科辉智药(深圳)新药研究中心有限公司 作为sarm1酶活性抑制剂的吡啶类化合物及其应用
WO2025179205A1 (en) * 2024-02-23 2025-08-28 Nura Bio, Inc. Methods for the treatment of neurological disorders
WO2026080488A1 (en) 2024-10-09 2026-04-16 Genentech, Inc. Heterocyclic compounds for the treatment of neurodegenerative diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020176863A1 (en) * 2019-02-28 2020-09-03 Kezar Life Sciences Thiazole derivatives as protein secretion inhibitors
WO2020247701A2 (en) * 2019-06-06 2020-12-10 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021142006A1 (en) * 2020-01-07 2021-07-15 Disarm Therapeutics, Inc. Inhibitors of sarm1

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9781098A (en) * 1997-10-02 1999-04-27 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2460345A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
DE102004009933A1 (de) 2004-02-26 2005-09-15 Merck Patent Gmbh Verwendung von Thiadiazolharnstoffderivaten
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US8236824B2 (en) 2007-10-09 2012-08-07 MERCK Patent Gesellschaft mit beschränkter Haftung N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators
WO2009114552A1 (en) 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2012049161A1 (en) 2010-10-13 2012-04-19 Glaxo Group Limited 3 -amino- pyrazole derivatives useful against tuberculosis
WO2012050141A1 (ja) 2010-10-14 2012-04-19 住友化学株式会社 ヘテロ芳香環化合物およびその有害生物防除用途
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・(ケイマン)・リミテッド Pde4阻害剤としての置換ピリジン及びピラジン化合物
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
WO2015140130A1 (en) 2014-03-17 2015-09-24 Remynd Nv Oxadiazole compounds
WO2015175704A1 (en) * 2014-05-14 2015-11-19 The Regents Of The University Of California Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
CA2955872A1 (en) 2014-07-24 2016-01-28 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
JP2018515623A (ja) 2015-05-18 2018-06-14 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としての複素環式化合物
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
EP3541806A4 (en) 2016-11-21 2020-07-01 Translational Drug Development, LLC HETEROCYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS
CA3108669A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
US12595252B2 (en) 2019-06-14 2026-04-07 Disarm Therapeutics, Inc. Inhibitors of SARM1
CA3150878A1 (en) * 2019-09-12 2021-03-18 Jonathan Bentley Inhibitors of sarm1
US12435084B2 (en) 2020-04-09 2025-10-07 Eli Lilly And Company Indazole derivatives as inhibitors of SARM1
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
TWI904906B (zh) 2020-08-24 2025-11-11 美商達薩瑪治療公司 Sarm1之抑制劑
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
EP4376840A4 (en) 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
EP4562001A1 (en) 2022-07-27 2025-06-04 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020176863A1 (en) * 2019-02-28 2020-09-03 Kezar Life Sciences Thiazole derivatives as protein secretion inhibitors
WO2020247701A2 (en) * 2019-06-06 2020-12-10 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021142006A1 (en) * 2020-01-07 2021-07-15 Disarm Therapeutics, Inc. Inhibitors of sarm1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY(STN)[ONLINE], JPN7026001219, ISSN: 0005825140 *

Also Published As

Publication number Publication date
US11629136B1 (en) 2023-04-18
KR20240041987A (ko) 2024-04-01
US20230105696A1 (en) 2023-04-06
US12110285B2 (en) 2024-10-08
WO2023009663A1 (en) 2023-02-02
CL2024000239A1 (es) 2024-06-07
CO2024001716A2 (es) 2024-03-07
US20230286941A1 (en) 2023-09-14
EP4376840A1 (en) 2024-06-05
IL310403A (en) 2024-03-01
CA3226869A1 (en) 2023-02-02
TW202313009A (zh) 2023-04-01
MX2024001322A (es) 2024-04-30
EP4376840A4 (en) 2025-05-21
AU2022320699A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
US12110285B2 (en) Substituted pyridine derivatives as SARM1 inhibitors
KR102161364B1 (ko) LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
US10669279B2 (en) Imidazopyridazine compounds
US10919885B2 (en) Compounds and uses thereof
CN113072542B (zh) RORγt抑制剂及其制备方法和用途
CN106061947B (zh) 环己基砜RORγ调节剂
US10131669B2 (en) Pyrazolopyrimidine compounds
US11945796B2 (en) Substituted pyridine derivatives as SARM1 inhibitors
AU6143899A (en) Fused pyridine inhibitors of cgmp phosphodiesterase
US10738063B2 (en) 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
JP2024529508A (ja) ピロロ[2,3-b]ピリジンPGDH阻害剤、および製造方法ならびに使用方法
EP4562001A1 (en) Substituted pyridine derivatives as sarm1 inhibitors
WO2025207539A1 (en) Sarm1 inhibitors
EA051437B1 (ru) Замещенные производные пиридина в качестве ингибиторов sarm1
CN118043046A (zh) 作为sarm1抑制剂的取代的吡啶衍生物
HK1237335B (zh) 咪唑并哒嗪化合物
OA19120A (en) Imidazopyridazine compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250704

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260325